Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37355001)

  • 1. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM; Üremiş N; Türköz Y
    Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin D Inhibits the Proliferation of HepG2 Cells and Induces Apoptosis by Modulating JAK/STAT3, PI3K/Akt/mTOR and MAPK Signaling Pathways.
    Mehdi Üremiş M; Üremiş N; Tosun E; Durhan M; Çiğremiş Y; Baysar A; Türköz Y
    Curr Cancer Drug Targets; 2022; 22(11):931-944. PubMed ID: 35786188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK/STAT3, MAPK/ERK, and AKT/mTOR signaling pathways in HepG2 cell line.
    Üremiş N; Üremiş MM; Çiğremiş Y; Tosun E; Baysar A; Türköz Y
    J Food Biochem; 2022 Oct; 46(10):e14333. PubMed ID: 35866877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
    Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
    Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
    Chen MY; Hsu CH; Setiawan SA; Tzeng DTW; Ma HP; Ong JR; Chu YC; Hsieh MS; Wu ATH; Tzeng YM; Yeh CT
    Phytomedicine; 2023 Jan; 108():154478. PubMed ID: 36265255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
    Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
    FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
    Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Da-Chai-Hu-Tang Formula inhibits the progression and metastasis in HepG2 cells through modulation of the PI3K/AKT/STAT3-induced cell cycle arrest and apoptosis.
    Duan ZW; Liu Y; Zhang PP; Hu JY; Mo ZX; Liu WQ; Ma X; Zhou XH; Wang XH; Hu XH; Wei SL
    J Ethnopharmacol; 2024 Sep; 331():118293. PubMed ID: 38705430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
    Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
    Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.